Brought to you by 
Schering-Plough gets rights to Anacor's nail fungus compound
Feb 2007
Executive Summary
Schering-Plough has licensed exclusive worldwide rights to Anacor Phamaceuticals' (therapeutics for inflammation and infectious diseases) AN2690. The topical antifungal is in Phase IIb for onychomycosis, an infection of the nail and nail bed.
Deal Industry
- Biotechnology
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
-
Drug Delivery
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R+D and Marketing-Licensing
- Includes Equity
- Includes Contract
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Schering-Plough gets rights to Anacor's nail fungus compound
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice